Reporting on circulating tumor DNA monitoring in metastatic cancer: From clinical validity to clinical utility

Caroline Brenner Thomsen*, Amanda Dandanell Juul, Anna Cecilie Lefèvre, Christina Glismand Truelsen, Edina Dizdarevic, Heidi Ryssel, Ina Mathilde Kjær, Karen Lycke Wind, Louise Bach Callesen, Louise Faaborg Larsen, Malene Støchkel Frank, Rikke Fredslund Andersen, Karen Lise Garm Spindler, Anders Jakobsen

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

35 Downloads (Pure)

Abstract

This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.

Original languageEnglish
JournalCancer
Volume128
Issue number11
Pages (from-to)2052-2057
ISSN0008-543X
DOIs
Publication statusPublished - Jun 2022

Keywords

  • circulating tumor DNA (ctDNA)
  • clinical utility
  • metastatic cancer
  • monitoring
  • reporting on circulating tumor DNA
  • standardization
  • Circulating Tumor DNA/genetics
  • Neoplasms, Second Primary
  • Humans
  • Mutation
  • Neoplasms/genetics
  • Biomarkers, Tumor/genetics

Fingerprint

Dive into the research topics of 'Reporting on circulating tumor DNA monitoring in metastatic cancer: From clinical validity to clinical utility'. Together they form a unique fingerprint.

Cite this